Gene
POLE4
DNA polymerase epsilon 4, accessory subunit
Explore in graph →CI-GENE-00020335HGNC:18755 ENSG00000115350 NCBI 56655 CIViC Approved
Curated evidence
Clinical evidence (1)
CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25765070
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| POLE4 A59E1 | ||||||||
| Pembrolizumab | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4775In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLE4 deleterious A59E mutation (as determined by Polyphen or SIFT), treated with pembrolizumab m… (full text at CIViC) PMID 25765070 · Rizvi et al., 2015 · Open in CIViC | civic |
Cohorts
Alteration frequency by cohort (0)
Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.
Data not yet available
No cohort frequency recorded for this gene.
Literature
Linked publications (0)
Data not yet available
No publication linked to this gene yet.